In six trading days, the share price rose 49.39%; In the next five trading days, it fell by 46.04%.
In just 11 trading days, the trend of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) can be described as “ups and downs, great joy and great sorrow”. The latest market value of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) is 7.271 billion yuan after a 5-day decline of 6.2 billion yuan. In the first and last 11 days, the turnover of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) was significantly enlarged, with a cumulative turnover of 19 billion yuan.
Today, according to the data disclosed by the Shenzhen Stock Exchange, small and medium-sized investors have bought Jiangxi Fushine Pharmaceutical Co.Ltd(300497) 4993 billion yuan in the past five trading days, accounting for 42.57%. Before the continuous sharp decline, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) important shareholders had accurately reduced their holdings at the high point.
share price halved in five days
On January 26, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) fell 7.10% again and closed at 13.22 yuan / share, down 55.03% from the high of 29.40 yuan / share on January 20.
Before cutting back in nearly five trading days, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) trend was strong. From January 12 to 19, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) 6 trading days increased by 49.39% in total, and the turnover increased steadily. In the past 11 trading days, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) has accumulated as high as 19 billion yuan.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) turnover since January 12
At that time, covid-19 drug concept stocks were hot fried in the market. On the interactive platform of Shenzhen Stock Exchange, some investors asked the company: whether to cooperate with world-famous pharmaceutical enterprises to develop and supply covid-19 pharmaceutical intermediates and APIs?
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) on January 14, the company replied that relying on the R & D foundation of lingfu Pharmaceutical Research Institute, the company has supplied kg samples to customers and passed the customer verification.
Source: Shenzhen Stock Exchange Interactive Trading Co., Ltd
After January 14, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) accelerated its rise and rose the limit on January 19.
On January 19, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) disclosed in the record of investor relations activities, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) said that at present, the company provides customers with core intermediates of mopiravir and redsiwade, which can be used to treat covid-19 pneumonia. Because the company has signed a strict confidentiality agreement with customers, it is inconvenient to disclose specific customer information. At the same time, it also said that the company is constantly strengthening R & D and cooperating with lingfu Pharmaceutical Research Institute. Now it has the R & D and production capacity of covid-19 therapeutic drug intermediates. The company expects to enter the supply chain system of covid-19 therapeutic drug production of Pfizer and other companies.
On January 20, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) 20% of the trading limit opened, but then fell rapidly, closing down 7.31% throughout the day, with a turnover of 5 billion yuan and a turnover rate of 42.59%.
On January 21, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) fell by the limit, with a turnover of 2.835 billion yuan. On January 24, it fell by 8.97%, with a turnover of 1.443 billion yuan. On January 25, it fell by 13.97%, with a turnover of 1.5 billion yuan. On January 26, it fell by 7.10% again, with a turnover of 948 million yuan.
Today’s closing price fell by 55.03% compared with the opening price on January 20 and 46.04% compared with the closing price on January 19.
the daily loss of the four hot money is 100 million yuan
Because of the sharp rise and fall, in recent trading days, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) has frequently been on the dragon and tiger list.
According to the Dragon Tiger list, on January 19, the Shenzhen Branch of East Asia Qianhai securities bought a net 103 million yuan, China Industrial Securities Co.Ltd(601377) Shanghai World Expo Road Securities Business Department bought a net more than 60 million yuan, Orient Securities Company Limited(600958) Shanghai Pudong New Area Yuanshen Road Securities Business Department, Sinolink Securities Co.Ltd(600109) Shanghai Pudong New area Meihua Road Securities business department all bought a net more than 42 million yuan, Zheshang Securities Co.Ltd(601878) Linhai Chonghe Road Securities Business Department Tianfeng Securities Co.Ltd(601162) Chengdu Baiyi Shangjie securities business department sold sharply and stopped making profits before the sharp decline.
On January 20, Minmetals Securities Shanghai Hankou Road Securities Business Department, Huatai Securities Co.Ltd(601688) Beijing East Third Ring North Road Securities Business Department and East Asia Qianhai securities Shenzhen Branch all sold more than 100 million yuan. Among them, East Asia Qianhai securities Shenzhen Branch bought a seat on January 19. If all the stocks bought on January 19 are sold on January 20, East Asia Qianhai securities Shenzhen Branch will lose 2.7 million yuan.
Among the top five seats bought on the 20th, the total net purchase of five seats, including Shengang securities Zhejiang branch, Caixin securities Hangzhou Xihu Road International Trade Center securities business department and Huafu securities Xiamen Jiahe Road Securities Business Department, exceeded 350 million yuan, and faced a sharp loss on the same day.
According to the data of the Dragon Tiger list on January 21, four of the top five seats bought on January 20 appeared in the top five seats sold on January 21, with a total sales of 219 million yuan. If the four hot money seats sell all the net purchases on the 20th on the 21st, they will suffer a total loss of nearly 100 million yuan, of which the Zhejiang branch of Shengang securities will suffer a loss of about 37 million yuan.
Today, the Shenzhen Stock Exchange disclosed the trading situation of various investors in Jiangxi Fushine Pharmaceutical Co.Ltd(300497) for nearly five trading days. During this period, small and medium-sized investors bought 4.993 billion yuan, accounting for 42.57%; Other natural persons sold 5.925 billion yuan, accounting for 50.52%.
It can be inferred from the net amount that small and medium-sized investors suffered serious losses in this slump.
According to the classification of investors and the account classification standard of the CSRC, small and medium-sized investors refer to the accounts with a market value of less than 3 million yuan among natural person investors according to the classification method of the CSRC, and other natural person investors refer to the accounts with a market value of more than 3 million yuan according to the classification method of the CSRC.
performance fell sharply and shareholders accurately reduced their holdings
On January 24, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) released the performance forecast for 2021. It is estimated that the net profit in 2021 will be 43.8 million yuan – 63.8 million yuan, a year-on-year decrease of 80.02% – 86.28%.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) said that the reasons for the performance changes include: the sharp rise in the price of raw materials for main products, resulting in a sharp increase in the company’s procurement costs; It is estimated that the impact of non recurring profits and losses on the company’s net profit is about – 70 million yuan to – 50 million yuan.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) announced on January 19 that after receiving the notice of reduction issued by Zhejiang Yongtai Technology Co .Ltd(002326) , Zhejiang Yongtai Technology Co .Ltd(002326) reduced 5.4156 million shares of the company through centralized bidding on January 13 and January 19, with more than half of the reduction. On January 19, it reduced its holdings of 2.577 million shares at the price of 21.30 yuan / share, just the day before the sharp decline.
The announcement of serious abnormal fluctuations in stock trading disclosed today Jiangxi Fushine Pharmaceutical Co.Ltd(300497) shows that Ke Dan, the wife of Bao Jianhua, the actual controller and chairman of the company, increased his holdings of 1265400 shares at an average price of 15.82 yuan / share on January 25. Based on the average price of 15.05 yuan / share for the previous five holdings, the current floating loss of KODAN’s holdings exceeds 12%.
Source: Jiangxi Fushine Pharmaceutical Co.Ltd(300497) announcement
Up to now, Kedan has increased its holdings by more than 38 million yuan. According to the increase announcement previously issued by Jiangxi Fushine Pharmaceutical Co.Ltd(300497) , Bao Jianhua and his spouse plan to increase their holdings by no less than 50 million yuan and no more than 100 million yuan.
